{
    "organizations": [],
    "uuid": "fc523121f46e6e98c17aac2f9aaa11563c3399e1",
    "author": "",
    "url": "https://www.reuters.com/article/brief-mallinckrodt-receives-fda-acceptan/brief-mallinckrodt-receives-fda-acceptance-of-stannsoporfin-new-drug-application-filing-idUSASB0C78P",
    "ord_in_thread": 0,
    "title": "BRIEF-Mallinckrodt Receives FDA Acceptance Of Stannsoporfin New Drug Application Filing",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 04 PM / Updated 8 minutes ago BRIEF-Mallinckrodt Receives FDA Acceptance Of Stannsoporfin New Drug Application Filing Reuters Staff Feb 23 (Reuters) - Mallinckrodt Plc: * MALLINCKRODT RECEIVES FDA ACCEPTANCE OF STANNSOPORFIN NEW DRUG APPLICATION FILING * MALLINCKRODT PLC - UNDER PRESCRIPTION DRUG USER FEE ACT, FDA HAS SET ITS ACTION DATE TO RESPOND TO STANNSOPORFIN NDA AS AUGUST 22, 2018 Source text for Eikon: Further company coverage:",
    "published": "2018-02-23T14:02:00.000+02:00",
    "crawled": "2018-02-23T14:21:04.004+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "receives",
        "fda",
        "acceptance",
        "stannsoporfin",
        "new",
        "drug",
        "application",
        "filing",
        "reuters",
        "staff",
        "feb",
        "reuters",
        "mallinckrodt",
        "plc",
        "mallinckrodt",
        "receives",
        "fda",
        "acceptance",
        "stannsoporfin",
        "new",
        "drug",
        "application",
        "filing",
        "mallinckrodt",
        "plc",
        "prescription",
        "drug",
        "user",
        "fee",
        "act",
        "fda",
        "set",
        "action",
        "date",
        "respond",
        "stannsoporfin",
        "nda",
        "august",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}